Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-05-05 00:00:00 ET · period of report 2025-05-02 · accession 0001787306-25-000085 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-05 | 2025-05-02 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | S - Sale | $15.19 | -11.4K | 913.8K | -1% | -$173.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-02 | S | D | 11,448 | $15.19 | 913,795 | D | — | — | (F1) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted on February 13, 2024. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.75 to $15.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |